Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
Under the partnership, the companies will utilize their expertise and resources to identify and analyze data and information with a focus on improving health care quality and outcomes. The partnership reflects a shared commitment by both companies to address the challenges of improving quality of care and reducing treatment costs in today's complex and changing health care environment.
"Pairing Humana's clinical expertise and rich, de-identified patient data with Lilly's history and experience across many disease states allows us to maximize the potential benefits for patient care and savings," said
Under the terms of the multi-year agreement, the companies will conduct a range of studies related to various disease states. Study methodologies include: impact of interventions on outcomes, adherence programs, disease management and pharmacoeconomics.
The initial project is aimed at investigating patient characteristics associated with increased health care costs in people with type 2 diabetes. This retrospective analysis utilizes de-identified medical, pharmacy and laboratory claims data, in addition to research algorithms focused on exploring patient attitudes and behaviors. Future studies may use this information to identify modifiable characteristics that can be targeted with behavioral and other therapeutic interventions.
"We are pleased to partner with
Comprehensive Health Insights (CHI), a wholly owned subsidiary of
About
More information regarding
- Annual reports to stockholders
Securities and Exchange Commission filings- Most recent investor conference presentations
- Quarterly earnings news releases
- Replays of most recent earnings release conference calls
- Calendar of events (including upcoming earnings conference call dates and times, as well as planned interaction with research analysts and institutional investors)
- Corporate Governance information
About
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in
C-LLY
FOR MORE INFORMATION, CONTACT:
Humana Corporate Communications
502-580-2990
akepnes@humana.com
317-701-4007
murphy_kelley@lilly.com
(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )
(Logo: http://photos.prnewswire.com/prnh/20130829/DE70165LOGO )
SOURCE
News Provided by Acquire Media